vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Xometry, Inc. (XMTR). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $192.4M, roughly 1.3× Xometry, Inc.). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs -4.5%, a 15.6% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 29.5%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $-5.9M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 25.2%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Xometry is an online marketplace for sourcing on-demand manufactured parts for prototyping and large-scale production.
ANIP vs XMTR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $192.4M |
| Net Profit | $27.5M | $-8.6M |
| Gross Margin | — | 39.1% |
| Operating Margin | 14.1% | -4.6% |
| Net Margin | 11.1% | -4.5% |
| Revenue YoY | 29.6% | 29.5% |
| Net Profit YoY | 367.5% | 12.7% |
| EPS (diluted) | $1.14 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $192.4M | ||
| Q3 25 | $227.8M | $180.7M | ||
| Q2 25 | $211.4M | $162.5M | ||
| Q1 25 | $197.1M | $151.0M | ||
| Q4 24 | $190.6M | $148.5M | ||
| Q3 24 | $148.3M | $141.7M | ||
| Q2 24 | $138.0M | $132.6M | ||
| Q1 24 | $137.4M | $122.7M |
| Q4 25 | $27.5M | $-8.6M | ||
| Q3 25 | $26.6M | $-11.6M | ||
| Q2 25 | $8.5M | $-26.4M | ||
| Q1 25 | $15.7M | $-15.1M | ||
| Q4 24 | $-10.3M | $-9.9M | ||
| Q3 24 | $-24.2M | $-10.2M | ||
| Q2 24 | $-2.3M | $-13.7M | ||
| Q1 24 | $18.2M | $-16.6M |
| Q4 25 | — | 39.1% | ||
| Q3 25 | — | 39.9% | ||
| Q2 25 | — | 40.1% | ||
| Q1 25 | — | 37.3% | ||
| Q4 24 | — | 39.7% | ||
| Q3 24 | — | 39.4% | ||
| Q2 24 | — | 39.9% | ||
| Q1 24 | — | 39.0% |
| Q4 25 | 14.1% | -4.6% | ||
| Q3 25 | 15.9% | -6.1% | ||
| Q2 25 | 6.6% | -6.3% | ||
| Q1 25 | 13.3% | -10.2% | ||
| Q4 24 | -2.3% | -7.8% | ||
| Q3 24 | -13.8% | -8.1% | ||
| Q2 24 | 3.7% | -11.5% | ||
| Q1 24 | 14.8% | -14.6% |
| Q4 25 | 11.1% | -4.5% | ||
| Q3 25 | 11.7% | -6.4% | ||
| Q2 25 | 4.0% | -16.3% | ||
| Q1 25 | 8.0% | -10.0% | ||
| Q4 24 | -5.4% | -6.7% | ||
| Q3 24 | -16.3% | -7.2% | ||
| Q2 24 | -1.7% | -10.3% | ||
| Q1 24 | 13.2% | -13.5% |
| Q4 25 | $1.14 | — | ||
| Q3 25 | $1.13 | — | ||
| Q2 25 | $0.36 | — | ||
| Q1 25 | $0.69 | — | ||
| Q4 24 | $-0.45 | — | ||
| Q3 24 | $-1.27 | — | ||
| Q2 24 | $-0.14 | — | ||
| Q1 24 | $0.82 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $219.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $275.6M |
| Total Assets | $1.4B | $703.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $219.1M | ||
| Q3 25 | $262.6M | $224.5M | ||
| Q2 25 | $217.8M | $225.8M | ||
| Q1 25 | $149.8M | $231.4M | ||
| Q4 24 | $144.9M | $239.8M | ||
| Q3 24 | $145.0M | $234.0M | ||
| Q2 24 | $240.1M | $240.9M | ||
| Q1 24 | $228.6M | $253.8M |
| Q4 25 | $540.7M | $275.6M | ||
| Q3 25 | $505.8M | $272.0M | ||
| Q2 25 | $436.8M | $270.4M | ||
| Q1 25 | $418.6M | $309.9M | ||
| Q4 24 | $403.7M | $314.5M | ||
| Q3 24 | $405.9M | $315.2M | ||
| Q2 24 | $455.8M | $315.8M | ||
| Q1 24 | $452.0M | $320.4M |
| Q4 25 | $1.4B | $703.7M | ||
| Q3 25 | $1.4B | $698.9M | ||
| Q2 25 | $1.3B | $687.0M | ||
| Q1 25 | $1.3B | $690.1M | ||
| Q4 24 | $1.3B | $680.1M | ||
| Q3 24 | $1.3B | $678.2M | ||
| Q2 24 | $920.8M | $678.6M | ||
| Q1 24 | $914.5M | $692.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $4.4M |
| Free Cash FlowOCF − Capex | $29.1M | $-5.9M |
| FCF MarginFCF / Revenue | 11.8% | -3.0% |
| Capex IntensityCapex / Revenue | 0.5% | 5.3% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $-24.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $4.4M | ||
| Q3 25 | $44.1M | $5.8M | ||
| Q2 25 | $75.8M | $-427.0K | ||
| Q1 25 | $35.0M | $-3.7M | ||
| Q4 24 | $15.9M | $9.1M | ||
| Q3 24 | $12.5M | $-3.6M | ||
| Q2 24 | $17.4M | $-9.1M | ||
| Q1 24 | $18.3M | $-11.7M |
| Q4 25 | $29.1M | $-5.9M | ||
| Q3 25 | $38.0M | $-1.7M | ||
| Q2 25 | $71.8M | $-7.4M | ||
| Q1 25 | $32.5M | $-9.2M | ||
| Q4 24 | $13.5M | $4.5M | ||
| Q3 24 | $7.7M | $-8.4M | ||
| Q2 24 | $13.0M | $-13.5M | ||
| Q1 24 | $13.7M | $-16.1M |
| Q4 25 | 11.8% | -3.0% | ||
| Q3 25 | 16.7% | -0.9% | ||
| Q2 25 | 34.0% | -4.5% | ||
| Q1 25 | 16.5% | -6.1% | ||
| Q4 24 | 7.1% | 3.1% | ||
| Q3 24 | 5.2% | -6.0% | ||
| Q2 24 | 9.4% | -10.2% | ||
| Q1 24 | 10.0% | -13.1% |
| Q4 25 | 0.5% | 5.3% | ||
| Q3 25 | 2.7% | 4.1% | ||
| Q2 25 | 1.9% | 4.3% | ||
| Q1 25 | 1.3% | 3.6% | ||
| Q4 24 | 1.3% | 3.1% | ||
| Q3 24 | 3.2% | 3.4% | ||
| Q2 24 | 3.2% | 3.3% | ||
| Q1 24 | 3.3% | 3.5% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
XMTR
| US | $159.1M | 83% |
| Non Us | $33.3M | 17% |
